Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/5/2019
SIETES contiene 92751 citas

 
 
 1 a 14 de 14 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]
2.Enlace a cita original Cita con resumen
Lopes RD, Rordorf R, De Ferrari GM, Leonardi S, Thomas L, Wojdyla DM, Ridefelt P, Lawrence JH, De Caterina R, Vinereanu D, Hanna M, Flaker G, Al-Khatib SM, Hohnloser SH, Alexander JH, Granger CB, Wallentin L, ARISTOTLE Committees and Investigators. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol 2018;71:13 de marzo. [Ref.ID 102547]
3. Cita con resumen
Fanning L, Ilomäki J, Bell JS, Darzinš P. The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. Eur J Clin Pharmacol 2017;73:1427-36. [Ref.ID 102129]
4.Enlace a cita original Cita con resumen
Focks JJ, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, Lanas F, Xavier D, Husted S, Wallentin L, Alexander JH, Granger CB, Verheught FWA. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ 2016;353:i2868. [Ref.ID 100461]
5.Tiene citas relacionadas Cita con resumen
Christopoulos C. Questions about the reliability of ROCKET-AF anticoagulation data. BMJ 2016;352:i1039. [Ref.ID 100063]
6.Enlace a cita originalTiene citas relacionadas Cita con resumen
Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]
7. Cita con resumen
Viles-Gonzalez JF, Halperin JL. Efficacy and safety of amiodarone in patients with atrial fibrillation in the era of target-specific anticoagulants. J Am Coll Cardiol 2014;64:1551-3. [Ref.ID 98230]
8. Cita con resumen
Ruff ChT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62. [Ref.ID 97286]
9. Cita con resumen
Hermann HC. Who will do well on warfarin? Does it matter?. Journal Watch Cardiology Alert 2013:19 de junio. [Ref.ID 95636]
10.Tiene citas relacionadas
Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Baht MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJV, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomsied controlled trial. Lancet 2012;380:1749-58. [Ref.ID 94073]
11.Tiene citas relacionadas
Vassilou VS, Flynn PD. Apixaban in atrial fibrillation: does predicted risk matter?. Lancet 2012;380:1718-9. [Ref.ID 94072]
12.
García-Bragado F. La medicina actual ante los anticoagulantes de nueva generación. Med Clin (Barc) 2012;138:438-40. [Ref.ID 92561]
13.Tiene citas relacionadas
Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med 2011;365:1052-4. [Ref.ID 90981]
14.Tiene citas relacionadas Cita con resumen
Granger CB. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92. [Ref.ID 90980]
Seleccionar todas
 
 1 a 14 de 14